Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Markets:
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

4.070 +0.170 (+4.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 234,078
Open 3.990
Bid (Size) 3.500 (2)
Ask (Size) 4.400 (1)
Prev. Close 3.900
Today's Range 3.850 - 4.100
52wk Range 2.945 - 9.700
Shares Outstanding 36,936,886
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDT 
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-11.3%
-11.3%
1 Month
-13.2%
-13.2%
3 Month
-37.4%
-37.4%
6 Month
-7.3%
-7.3%
1 Year
-47.3%
-47.3%

More News

Read More
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
Via Benzinga
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in the BMO Oncology Summit
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
From Foghorn Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Foghorn Therapeutics Inc. - Common Stock publicly traded?
Yes, Foghorn Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Foghorn Therapeutics Inc. - Common Stock trade on?
Foghorn Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Foghorn Therapeutics Inc. - Common Stock?
The ticker symbol for Foghorn Therapeutics Inc. - Common Stock is FHTX on the Nasdaq Stock Market
What is the current price of Foghorn Therapeutics Inc. - Common Stock?
The current price of Foghorn Therapeutics Inc. - Common Stock is 4.070
When was Foghorn Therapeutics Inc. - Common Stock last traded?
The last trade of Foghorn Therapeutics Inc. - Common Stock was at 10/24/25 04:00 PM ET
What is the market capitalization of Foghorn Therapeutics Inc. - Common Stock?
The market capitalization of Foghorn Therapeutics Inc. - Common Stock is 150.33M
How many shares of Foghorn Therapeutics Inc. - Common Stock are outstanding?
Foghorn Therapeutics Inc. - Common Stock has 150M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.